Abstract:FK 506 has proven to be an effective immunosuppressive agent in liver transplantation, but its role in renal transplantation remains to be defined. Since the initial availability of FK 506 for treatment of refractory renal allograft rejection, we have applied an aggressive approach consisting of institution of rescue therapy at an early point in the rejection process combined with assiduous monitoring of FK 506 blood levels and the histologic response to therapy. A total of 17 adult patients were treated for refractory renal allograft rejection with this approach. Median follow‐up was 9 months post‐initiation of FK 506 therapy. Median time to first rejection was 26 d post‐transplant, and median time to FK 506 rescue therapy was 113 d post‐transplant. Sixteen of 17 patients received either ATGAM or OKT3 induction therapy. Prior to FK 506 rescue therapy, patients received the following antirejection therapy: corticosteroids 40+21 mg/kg (prednisone or Solumedrol), OKT3 (median 14 d), ATGAM (3 patients, 14 d each). FK 506 rescue therapy was successful in reversing the rejection process in all 17 patients. Fifteen patients (88%) demonstrated rapid reversal of rejection (i.e. reversal within 14 d), whereas three patients demonstrated delayed reversal. Nine month actuarial patient and graft survivals were 92% and 84%. When censored for documented noncompliance, nine month actuarial graft survival was 92%. Good long‐term renal function was observed (pre‐FK 506 baseline creatinine 2.1±0.5 mg/dl, current serum creatinine 2.1±0.6 mg/dl. Six recurrent rejection episodes occurred in 5 patients (29%) with a median time to recurrent rejection of 59 d post‐initiation of FK 506 rescue therapy. Each recurrent rejection episode was successfully treated by corticosteroids and/or increased FK 506 dose. CMV disease and lymphoma were not observed. Histologic evidence of FK 506 nephrotoxicity (hyaline necrosis in preglomerular arterioles) was observed in 6 patients 30% (median) time to diagnosis 49 d). FK 506 blood levels (whole blood TDX) between 10 and 20 ng/ml provided effective reversal in most patients. Current FK 506 dose and blood levels are 0.18±0.09 mg/kg/d and 7±2 ng/dl). FK 506 rescue therapy also allowed aggressive reductions in prednisone dose: (mean current prednisone dose 0.08±0.05 mg/kg/d). In conclusion, an aggressive approach toward FK 506 rescue: 1) provides prompt, effective reversal of refractory renal allograft rejection, 2) good long‐term renal allograft function, 3) balanced immunosuppression with respect to recurrent rejection, opportunistic infection and PTLD, 4) acceptable toxicity, and 5) aggressive reduction in corticosteroid dosing. Based on these findings, FK 506 rescue therapy is now the treatment of choice in our program for renal allograft rejection episodes that occur following antilymphocyte antibody therapy.

FK506 promotes liver regeneration by suppressing natural killer cell activity

Optimal immunosuppressor induces stable gut microbiota after liver transplantation.

FK506 contributes to peripheral nerve regeneration by inhibiting neuroinflammatory responses and promoting neuron survival

Tacrolimus inhibits NF-κB activity and lymphotactin gene expression after heart transplantation in mouse

Acute Influence of FK506 on T-Lymphocyte Populations of Peripheral Blood and Spleen in Rats

Immunotherapeutic and monitoring of tacrolimus in recipients of liver transplantation

FK506 induces lung lymphatic endothelial cell senescence and downregulates LYVE-1 expression, with associated decreased hyaluronan uptake

Isoglycyrrhizinate Magnesium Enhances Hepatoprotective Effect of FK506 on Ischemia-Reperfusion Injury Through HMGB1 Inhibition in a Rat Model of Liver Transplantation.

Tacrolimus promotes hepatocellular carcinoma and enhances CXCR4/SDF‑1α expression in vivo.

FK 506 therapy for refractory renal allograft rejection: lessons from liver transplantation

The Comparison of Two Immunosuppression Schemes Containing Tacrolimus in Renal Transplant Recipients

[Study on the Effect of Immunosuppressive Agent FK506 on Growth and Migration of Lung Cancer Cell].

Influential Factors and Regulation of FK506 C/D after Liver Transplantation

Comparison of the efficacy of low-dosage versus standard-dosage tacrolimus after kidney transplantation by programming renal biopsies

Effect of Kaempferol on Tacrolimus-Induced Nephrotoxicity and Calcineurin B1 Expression Level in Animal Model

The Application of FK506 Based Quadruple Immunosuppression Therapy in Clinical Liver Transplantation

Effect of Switch from Cyclosporine to FK506 on Renal Graft Outcome in Patients after Initial Acute Rejection

Comparative effects of hepatocyte growth factor and tacrolimus on acute liver allograft early tolerance

A Pilot Clinical Study of Tacrolimus(fk506) in Cadavaric Renal Transplant Recipients with Delayed Graft Function and Early Acute Rejection

Effect of FK506 in reducing scar formation by inducing fibroblast apoptosis after sciatic nerve injury in rats

FK 506 rescue therapy for hepatic allograft rejection: Experience with an aggressive approach